Equities Analysts Offer Predictions for SXTP Q2 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of 60 Degrees Pharmaceuticals in a report released on Wednesday, May 20th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.58) per share for the quarter, down from their previous forecast of ($0.53). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.84) EPS and FY2026 earnings at ($3.14) EPS.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.44 million.

Other research analysts also recently issued research reports about the stock. Ascendiant Capital Markets dropped their target price on shares of 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 12th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $14.10.

60 Degrees Pharmaceuticals Stock Performance

60 Degrees Pharmaceuticals stock opened at $1.49 on Friday. The stock has a market capitalization of $3.96 million, a price-to-earnings ratio of -0.11 and a beta of 2.69. 60 Degrees Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $14.68. The stock’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $2.86.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.